DAP12 Stabilizes the C-terminal Fragment of the Triggering Receptor Expressed on Myeloid Cells-2 (TREM2) and Protects against LPS-induced Pro-inflammatory Response*

Background: TREM2 is a DAP12-coupled receptor associated with neurodegenerative diseases. Results: Co-expression of DAP12 increased the level of TREM2 C-terminal fragment (TREM2-CTF) which suppressed the release of pro-inflammatory cytokines. Conclusion: A major function of DAP12 is to stabilize TREM2-CTF, which regulates inflammatory responses in microglia. Significance: Our studies unraveled a novel function of DAP12 and provided new link between TREM2/DAP12 complexes and neuroinflammation. Triggering receptor expressed on myeloid cells 2 (TREM2) is a DAP12-associated receptor expressed in microglia, macrophages, and other myeloid-derived cells. Previous studies have suggested that TREM2/DAP12 signaling pathway reduces inflammatory responses and promotes phagocytosis of apoptotic neurons. Recently, TREM2 has been identified as a risk gene for Alzheimer disease (AD). Here, we show that DAP12 stabilizes the C-terminal fragment of TREM2 (TREM2-CTF), a substrate for γ-secretase. Co-expression of DAP12 with TREM2 selectively increased the level of TREM2-CTF with little effects on that of full-length TREM2. The interaction between DAP12 and TREM2 is essential for TREM2-CTF stabilization as a mutant form of DAP12 with disrupted interaction with TREM2 failed to exhibit such an effect. Silencing of either Trem2 or Dap12 gene significantly exacerbated pro-inflammatory responses induced by lipopolysaccharides (LPS). Importantly, overexpression of either full-length TREM2 or TREM2-CTF reduced LPS-induced inflammatory responses. Taken together, our results support a role of DAP12 in stabilizing TREM2-CTF, thereby protecting against excessive pro-inflammatory responses.

[1]  B. Loriod,et al.  Temporal gene profiling of the 5XFAD transgenic mouse model highlights the importance of microglial activation in Alzheimer’s disease , 2014, Molecular Neurodegeneration.

[2]  J. Molinuevo,et al.  TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis , 2014, Science Translational Medicine.

[3]  A. Pestronk,et al.  TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. , 2014, JAMA neurology.

[4]  P. Deyn,et al.  Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia , 2014, Neurobiology of Aging.

[5]  Rui Huang,et al.  SQSTM1 mutations in Han Chinese populations with sporadic amyotrophic lateral sclerosis , 2014, Neurobiology of Aging.

[6]  C. Lemere Immunotherapy for Alzheimer’s disease: hoops and hurdles , 2013, Molecular Neurodegeneration.

[7]  H. Neumann,et al.  Sequential Proteolytic Processing of the Triggering Receptor Expressed on Myeloid Cells-2 (TREM2) Protein by Ectodomain Shedding and γ-Secretase-dependent Intramembranous Cleavage* , 2013, The Journal of Biological Chemistry.

[8]  E. Masliah,et al.  Microglial Beclin 1 Regulates Retromer Trafficking and Phagocytosis and Is Impaired in Alzheimer’s Disease , 2013, Neuron.

[9]  C. Cruchaga,et al.  TREM2 is associated with the risk of Alzheimer's disease in Spanish population , 2013, Neurobiology of Aging.

[10]  L. Tran,et al.  Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease , 2013, Cell.

[11]  A. Singleton,et al.  TREM2 variants in Alzheimer's disease. , 2013, The New England journal of medicine.

[12]  A. Hofman,et al.  Variant of TREM2 associated with the risk of Alzheimer's disease. , 2013, The New England journal of medicine.

[13]  Hiroaki Ito,et al.  TREM‐2, triggering receptor expressed on myeloid cell‐2, negatively regulates TLR responses in dendritic cells , 2012, European journal of immunology.

[14]  C. Koh,et al.  γ-Secretase-Regulated Mechanisms Similar to Notch Signaling May Play a Role in Signaling Events, Including APP Signaling, Which Leads to Alzheimer’s Disease , 2011, Cellular and Molecular Neurobiology.

[15]  Nick C Fox,et al.  Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease , 2011, Nature Genetics.

[16]  R. Veerhuis,et al.  Neuroinflammation – An Early Event in Both the History and Pathogenesis of Alzheimer’s Disease , 2010, Neurodegenerative Diseases.

[17]  L. Kiemeney,et al.  Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer , 2009, Nature Genetics.

[18]  W. Seaman,et al.  A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia , 2009, Journal of neurochemistry.

[19]  L. Lanier DAP10‐ and DAP12‐associated receptors in innate immunity , 2009, Immunological reviews.

[20]  Christoph Lange,et al.  Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. , 2008, American journal of human genetics.

[21]  Katrin Marcus,et al.  The amyloid precursor protein intracellular domain (AICD) as modulator of gene expression, apoptosis, and cytoskeletal dynamics—Relevance for Alzheimer's disease , 2008, Progress in Neurobiology.

[22]  L. Muglia,et al.  Amyloid Precursor Protein Regulates Brain Apolipoprotein E and Cholesterol Metabolism through Lipoprotein Receptor LRP1 , 2007, Neuron.

[23]  Huaxi Xu,et al.  Presenilin/γ-secretase-dependent processing of β-amyloid precursor protein regulates EGF receptor expression , 2007, Proceedings of the National Academy of Sciences.

[24]  H. Neumann,et al.  TREM2-Transduced Myeloid Precursors Mediate Nervous Tissue Debris Clearance and Facilitate Recovery in an Animal Model of Multiple Sclerosis , 2007, PLoS medicine.

[25]  J. Meldolesi,et al.  Triggering receptor expressed in myeloid cells 2 (TREM2) trafficking in microglial cells: Continuous shuttling to and from the plasma membrane regulated by cell stimulation , 2006, Neuroscience.

[26]  L. Piccio,et al.  Cutting Edge: TREM-2 Attenuates Macrophage Activation1 , 2006, The Journal of Immunology.

[27]  L. Lanier,et al.  Cutting Edge: Inhibition of TLR and FcR Responses in Macrophages by Triggering Receptor Expressed on Myeloid Cells (TREM)-2 and DAP121 , 2006, The Journal of Immunology.

[28]  J. Cobb,et al.  DAP12 (KARAP) amplifies inflammation and increases mortality from endotoxemia and septic peritonitis , 2005, The Journal of experimental medicine.

[29]  L. Lanier,et al.  Enhanced Toll-like receptor responses in the absence of signaling adaptor DAP12 , 2005, Nature Immunology.

[30]  H. Neumann,et al.  Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2 , 2005, The Journal of experimental medicine.

[31]  R. Spreafico,et al.  Distribution and signaling of TREM2/DAP12, the receptor system mutated in human polycystic lipomembraneous osteodysplasia with sclerosing leukoencephalopathy dementia , 2004, The European journal of neuroscience.

[32]  P. Greengard,et al.  Presenilins and γ-Secretase Inhibitors Affect Intracellular Trafficking and Cell Surface Localization of the γ-Secretase Complex Components* , 2004, Journal of Biological Chemistry.

[33]  M. Colonna TREMs in the immune system and beyond , 2003, Nature Reviews Immunology.

[34]  J. Sutcliffe,et al.  Heterogeneous expression of the triggering receptor expressed on myeloid cells‐2 on adult murine microglia , 2002, Journal of neurochemistry.

[35]  L. Peltonen,et al.  Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. , 2002, American journal of human genetics.

[36]  O. Salonen,et al.  CNS manifestations of Nasu–Hakola disease , 2001, Neurology.

[37]  M. Colonna,et al.  TREM-1 amplifies inflammation and is a crucial mediator of septic shock , 2001, Nature.

[38]  L. Lanier,et al.  The ITAM-bearing transmembrane adaptor DAP12 in lymphoid and myeloid cell function. , 2000, Immunology today.

[39]  M. Colonna,et al.  Cutting Edge: Inflammatory Responses Can Be Triggered by TREM-1, a Novel Receptor Expressed on Neutrophils and Monocytes1 , 2000, The Journal of Immunology.

[40]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[41]  Raphael Kopan,et al.  Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain , 1998, Nature.

[42]  Jun Wu,et al.  Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells , 1998, Nature.

[43]  H. Kettenmann,et al.  An immortalized cell line expresses properties of activated microglial cells , 1992, Journal of neuroscience research.

[44]  P. Greengard,et al.  Processing of Alzheimer beta/A4 amyloid precursor protein: modulation by agents that regulate protein phosphorylation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[45]  D. Campion,et al.  TREM2 R47H variant as a risk factor for early-onset Alzheimer's disease. , 2013, Journal of Alzheimer's disease : JAD.

[46]  R. Petersen,et al.  neurodegeneration : evidence for association of the p . R 47 H variant with frontotemporal dementia and Parkinson ¿ s disease Permalink , 2013 .

[47]  A. Singleton,et al.  TREM2 Variants in Alz hei mer's Disease , 2012 .

[48]  Nick C Fox,et al.  Common variants at ABCA 7 , MS 4 A 6 A / MS 4 A 4 E , EPHA 1 , CD 33 and CD 2 AP are associated with Alzheimer ’ s disease , 2011 .

[49]  Huaxi Xu,et al.  Presenilin/gamma-secretase-dependent processing of beta-amyloid precursor protein regulates EGF receptor expression. , 2007, Proceedings of the National Academy of Sciences of the United States of America.